Myriad Genetics (MYGN) AI Stock Analysis

• Market Cap: $561.06M
• Dividend Yield: N/A
• Average Volume (3M): 1.94M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.82
• Revenue Growth: 3.83%
• EPS Growth: -137.31%
• Country: US
• Employees: 2,700
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.05
• Shares Outstanding: 93,044,624
• 10 Day Avg. Volume: 3,487,060
• 30 Day Avg. Volume: 1,942,820
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 0.69
• Enterprise Value/Gross Profit: 0.98
• Enterprise Value/Ebitda: -9.34
• 1Y Price Target: $6.63
• Price Target Upside: 9.95% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 9

• Rating: 51 Neutral
• Price Target: $6.00 ▼(-0.50% Downside)

The overall stock score of 51 reflects significant financial challenges, including declining revenues and persistent losses, which weigh heavily on the score. However, positive developments from the earnings call and recent corporate events, such as the credit agreement, provide some optimism for future growth. Technical indicators suggest caution due to potential overbought conditions.

Positive Factors

Financial Performance

The adjusted EBITDA guidance has been increased, suggesting improved financial expectations.

Management Actions

Management appears willing to take decisive actions to improve the company, such as focusing on profitable growth and canceling unsuccessful business ventures.

Revenue Guidance

The company raised its revenue guidance by $8 million, indicating a potential rebound in performance.

Negative Factors

Competition

Intensifying competitive pressures in NIPT and in hereditary cancer testing are limiting growth potential longer term.

Long-term Potential

There is still a lack of clarity on MYGN's long-term potential, especially in its pressured non-oncology businesses.

Market Performance

The reduced price target from $15 to $7 indicates lowered expectations for the company's performance.

Myriad Genetics Business Overview & Revenue Model

Company Description

Myriad Genetics, Inc. is a molecular diagnostics company based in the United States that focuses on developing and commercializing innovative genetic tests. The company operates in the healthcare sector and specializes in precision medicine, primarily through its offerings in hereditary cancer testing, autoimmune disease testing, and pharmacogenomics. Myriad's core products include tests that assess the risk of cancer and help tailor treatment options based on genetic information, providing crucial insights for patients and healthcare providers.

How the Company Makes Money

Myriad Genetics generates revenue primarily through the sale of its genetic testing services. The company operates a fee-for-service model, where healthcare providers order tests for patients, and Myriad bills the insurers or patients directly. Key revenue streams include the hereditary cancer testing segment, which assesses genetic mutations in patients to evaluate their cancer risk, and the myRisk test that evaluates multiple cancer types simultaneously. Additionally, Myriad earns income from its pharmacogenomic tests that help determine how patients metabolize certain medications, enhancing treatment efficacy. The company has also established significant partnerships with various healthcare organizations and payers, which facilitates broader access to its tests and enhances its market presence. Factors contributing to earnings include increasing awareness and demand for genetic testing, advancements in technology, and the growing emphasis on personalized medicine.

Myriad Genetics Financial Statement Overview

Summary

The company faces declining revenues and persistent losses impacting profitability. While the balance sheet appears stable with a solid equity position, significant operational challenges remain.

Income Statement

The income statement shows a decline in revenue from $837.6M to $831.3M in TTM, indicating a negative revenue growth. The gross profit margin remains relatively stable with slight fluctuations, while net income remains negative, impacting net profit margins significantly. The company is experiencing negative EBIT and EBITDA margins, suggesting ongoing operational challenges.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio, with total debt increasing slightly but still manageable. The equity ratio is strong, indicating a solid asset base supported by equity. However, the return on equity is negative due to consistent net losses, signaling inefficiencies in generating shareholder value.

Cash Flow

Cash flow analysis reveals a negative operating cash flow, which has improved slightly in TTM. Free cash flow remains negative, indicating challenges in funding operations without external financing. The operating cash flow to net income ratio is negative, highlighting issues in converting income into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	837.60M	753.20M	678.40M	690.60M	557.00M
Gross Profit	585.40M	517.00M	476.40M	493.00M	378.80M
EBITDA	-59.50M	-186.10M	-67.80M	14.10M	-123.40M
Net Income	-127.30M	-263.30M	-112.00M	-27.20M	-223.70M
Balance Sheet
Total Assets	1.03B	1.15B	1.20B	1.32B	1.42B
Cash, Cash Equivalents and Short-Term Investments	102.40M	140.90M	114.90M	339.80M	150.70M
Total Debt	140.30M	152.10M	145.00M	92.30M	0.00
Total Liabilities	326.50M	363.30M	312.90M	352.90M	537.80M
Stockholders Equity	701.10M	783.20M	885.80M	967.80M	881.00M
Cash Flow
Free Cash Flow	-38.40M	-184.20M	-151.60M	600.00K	-40.10M
Operating Cash Flow	-8.70M	-110.90M	-106.30M	18.60M	-26.90M
Investing Cash Flow	-11.90M	31.90M	-77.50M	274.40M	61.60M
Financing Cash Flow	-7.40M	152.90M	-8.00M	-150.60M	-1.00M

Myriad Genetics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYGN, the sentiment is Neutral. The current price of 6.03 is above the 20-day moving average (MA) of 4.78, above the 50-day MA of 5.03, and below the 200-day MA of 10.11, indicating a neutral trend. The MACD of 0.23 indicates Negative momentum. The RSI at 64.84 is Neutral, neither overbought nor oversold. The STOCH value of 89.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MYGN.

Myriad Genetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	68 Neutral	$626.48M	11.53	20.73%	―	14.72%	―
FLGT	60 Neutral	$643.10M	―	-4.54%	―	4.31%	69.57%
GRAL	58 Neutral	$1.21B	―	-17.68%	―	22.37%	86.08%
CSTL	56 Neutral	$555.80M	30.59	-2.15%	―	20.40%	-165.41%
Sector *	51 Neutral	$7.41B	-0.29	-44.86%	2.30%	23.46%	-0.02%
MYGN	51 Neutral	$561.06M	―	-70.03%	―	3.83%	-137.31%
NEO	44 Neutral	$751.82M	―	-11.76%	―	9.70%	-30.94%

Myriad Genetics Corporate Events

Myriad Genetics Secures $200 Million Credit Agreement

On July 31, 2025, Myriad Genetics entered into a $200 million credit agreement with OrbiMed Royalty & Credit Opportunities IV, LP, which includes a $125 million initial loan and an option for an additional $75 million until June 30, 2027. This credit facility, secured by Myriad’s assets, will support the company’s working capital needs and growth strategy, replacing its previous ABL facility.

The most recent analyst rating on (MYGN) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Myriad Genetics stock, see the MYGN Stock Forecast page.